MECHELEN, BELGIUM--(Marketwire - July 24, 2012) - - Galapagos NV (EURONEXT BRUSSELS: GLPG)
that it has identified the first pre-clinical candidate compound in
osteoarthritis alliance with Servier. The compound inhibits a novel
of action discovered by Galapagos. This achievement triggered an
milestone payment to Galapagos.
In July 2010, Servier and Galapagos announced their alliance to develop new
medicines for the treatment of osteoarthritis (OA). Galapagos is
for the discovery and development of new candidate drugs, and Servier has
exclusive option to license these after the completion of Phase I
trials. Galapagos retains exclusive US commercialization rights to
"OA is a disease of high unmet medical need, and progress of OA-therapies
been slow in the pharma industry. We therefore are very pleased to
delivered a pre-clinical candidate," said Onno van de Stolpe, Chief
Officer of Galapagos. "This achievement also marks the third alliance with
different pharma partner in which Galapagos has identified a pre-
candidate. We are now starting with all the preparations to proceed
into Phase I."
"It is a major achievement in this therapeutic area where no disease-
treatments are currently available," said Bernard Marchand, Head of
Research at Servier. "We are looking forward to seeing this compound
enter the clinic after successful completion of the remaining pre-
requirements and are encouraged in our efforts to change the lives of
suffering from this debilitating disease."
About Galapagos' osteoarthritis alliance with Servier
The alliance between Servier and Galapagos builds on novel osteoarthritis
targets discovered by Galapagos through its proprietary platform. For
marketed products, Servier will have the rights to development, registration
commercialization, but Galapagos retains exclusive U.S.
rights. Galapagos is also eligible to receive discovery,
regulatory and other milestone payments that could reach EUR290 million,
royalties upon commercialization of products outside the U.S. covered under
Osteoarthritis (OA) is the most common form of arthritis, typically
people aged 45 and older. It is a degenerative disease characterized by
destruction and loss of cartilage. No currently available treatments prevent
or even reverse or block the disease process. Treatment of OA involves
control, exercise, and pain relief, most frequently with non-steroidal
anti-inflammatory drugs (NSAIDs) that relieve the symptoms without
course of the underlying disease. Many OA patients have pain that
despite these measures and often then have to undergo costly surgical
to replace their damaged joints. It is expected that with the aging of
population, more individuals will be prone to develop OA. As mobility
seniors is of high importance to maintaining a high quality of life,
the severity of OA is seen as an immense clinical need over the next decade.
Servier is a privately-run research based pharmaceutical company with a
turnover of EUR3.9 billion. Servier is dedicating 25% of its turnover to
& Development in cardiovascular, metabolic, neurological, psychiatric and
and joint diseases as well as oncology. Servier is established in 140
worldwide with over 20,000 employees. More info at: www.servier.com
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a mid-size
specialized in the discovery and development of small molecule and
therapies with novel modes-of-action. The Company is progressing its
inhibitor GLPG0634, as well as one of the largest pipelines in biotech,
four programs in development and over 30 discovery programs. The
Group has about 800 employees and operates facilities in six countries,
global headquarters in Mechelen, Belgium. More info at: www.glpg.com
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
and "continues," as well as similar expressions. Such forward-
statements may involve known and unknown risks, uncertainties and other
which might cause the actual results, financial condition, performance
achievements of Galapagos, or industry results, to be materially different
any historic or future results, financial conditions, performance
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak only
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE